AbbVie Inc. (ABBV)

NYSE : Health Technology
Prev Close 88.73
Day Low/High 87.33 / 89.09
52 Wk Low/High 62.66 / 92.99
Avg Volume 7.52M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 131.22B
EPS 3.70
P/E Ratio 38.03
Div & Yield 4.72 (4.94%)
Earnings Growth Boosts AbbVie

Earnings Growth Boosts AbbVie

Drug franchises are still going strong.

Mylan Deal Is All That Shell Is Not

The ecstasy and the agony of M&A all in one day.

Portfolio Managers Shop for Growth

Combined Heinz-Kraft heads a long second-quarter list.

Biotech, Chips Stand Their Ground

You can't help but feel better about both groups.

Biotechs Need to Rest

If there is no catalyst, I'd join those who sell on a bounce.

Backing Away From Biotechs

This sector could see some real damage.

Biotech Stocks at a Crossroad

Own them, or take something off the table?

These Stocks Get Benefit of the Doubt

Market backtracks on skepticism over biotechs.

Market Rewards Biotech Latecomers

It shouldn't be possible, but it never seems too late to get in.

Jobs Report and Biotech Nerves

I am happy to be standing in for Doug Kass today on the Daily Diary. The market-moving event du jour is likely to be the jobs report, which hits an hour before the open. Hopefully it will show the American economy continues to add jobs at the same r...

That's Just What's Supposed to Happen

Stocks that stabilized yesterday were terrific today.

Value in Good Management

Kroger is a good example of execution.

Recommended Reading, Part Deux

In Jim "El Capitan" Cramer's "Return of the Cult Stocks," he talks about comebacks in Tesla (TSLA), Facebook (FB), Netflix (NFLX), Amazon (AMZN) and others -- even Ali Blah Blah (BABA) and GoPro (GPRO) have had a rally, albeit from depressed levels....

Cramer: Return of the Cult Stocks

The cult of the buyer stays devoted to Tesla, Netflix, Amazon and more.

China Cuts Growth Target

And four other things you need to know now.

Dynavax Technologies: A New 'Best Idea'

Dynavax Technologies: A New 'Best Idea'

This vaccine maker is now closer to several important milestones.

Why I Favor Big-Cap Growth Stocks

Why I Favor Big-Cap Growth Stocks

Because now is not the time to get complacent in this market.

From the Street of Dreams

Deutsche Bank reiterates its Buy recommendation on Gilead (GILD) (price target $125) based on the company's exclusive agreement with AbbVie (ABBV) for its HCV drug.

The Biotechs Are Back

Watch this leadership group that's been lagging.

There Are Still a Few Bargains Around

There Are Still a Few Bargains Around

They're in the tech, pharma and biotechnology sectors.

Abbvie rated new Sell at Citi

Abbvie estimates, target reduced at BMO

Getting Defensive Now

Getting Defensive Now

I am adding allocation to healthcare.

JP Morgan Healthcare Conf.

Abbvie downgraded at BofA/Merrill

Why I'm Sticking With Biotech

Why I'm Sticking With Biotech

They offer a nice shelter for the headwinds now hitting equities.

Gilead Is Set to Surge

Its hepatitis C drug will dominate the market.

Gilead Is a Buying Opportunity

Gilead Is a Buying Opportunity

Its hepatitis C drug is better; the stock trades at a discount.

Heed the Rotation

Stocks that do well when the economy rises are shining.